Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2018 07:00 ET | Source: Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a calcium release-activated calcium (CRAC) channel inhibitor and RP10107, a glutaminase inhibitor at the 2018 AACR Annual Meeting

La Chaux-de-Fonds, Switzerland, April 10, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor and...
October 24, 2017 07:00 ET | Source: Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class oral small molecule inhibitor of calcium release-activated calcium (CRAC) channel at 2017 AACR-NCI-EORTC International Conference, USA

La Chaux-de-Fonds, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor in hematological...
September 06, 2013 06:03 ET | Source: Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals S.A. announces scientific presentations on the therapeutic potential of their lead dual PI3K delta/gamma inhibitor and CRAC channel inhibitor at the ERS Annual Conference at Barcelona, Spain, 7-11 September 2013

La Chaux-de-Fonds, Switzerland, Sept. 6, 2013 (GLOBE NEWSWIRE) -- La Chaux-de-Fonds, Switzerland (6 September 2013): Rhizen Pharmaceuticals S.A. announces a scientific poster presentation on the...